{"id":"cev-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Infection risk"}]},"_chembl":{"chemblId":"CHEMBL4297950","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CEV typically refers to a chemotherapy combination regimen, though the exact composition may vary by institution. Common interpretations include combinations of cyclophosphamide, etoposide, and vincristine or similar agents. These drugs work through different mechanisms—alkylating agents cross-link DNA, topoisomerase inhibitors prevent DNA repair, and vinca alkaloids disrupt microtubule formation—creating a multi-modal attack on rapidly dividing cancer cells.","oneSentence":"CEV is a combination chemotherapy regimen that uses multiple cytotoxic agents to inhibit cancer cell division and induce apoptosis.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:43:18.245Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Lymphomas and hematologic malignancies (specific indications vary by institution)"}]},"trialDetails":[{"nctId":"NCT00110110","phase":"PHASE2","title":"Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Hospital for Sick Children","startDate":"2004-06","conditions":"Retinoblastoma","enrollment":71},{"nctId":"NCT00500890","phase":"PHASE3","title":"Treatment of Tumors of the Choroid Plexus Epithelium","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-09-02","conditions":"Choroid Plexus Tumors","enrollment":2},{"nctId":"NCT02319486","phase":"PHASE4","title":"CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2009-01","conditions":"Retinoblastoma","enrollment":26},{"nctId":"NCT02137928","phase":"PHASE3","title":"Carboplatin Periocular Injection for Retinoblastoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2006-01","conditions":"Retinoblastoma","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["carboplatin,vincristine, etoposide"],"phase":"marketed","status":"active","brandName":"CEV chemotherapy","genericName":"CEV chemotherapy","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CEV is a combination chemotherapy regimen that uses multiple cytotoxic agents to inhibit cancer cell division and induce apoptosis. Used for Lymphomas and hematologic malignancies (specific indications vary by institution).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}